How Does VigorHorse Work?

The left two columns come off the label. The third is what the published studies ran. The fourth is division.

Setting them out this way is the fastest route to an honest expectation. One of the four routes has a disclosed amount on the panel. One has a large literature at a hundred times this total. One has a literature at twenty to sixty times it. One has no human outcome data at all.

That is not a reason to dismiss the jar; it is a reason to know which lever is actually available. A small, reliable stimulant taken at the same time every day is a real thing to have. Sixty-five milligrams of arginine is not going to change a vascular measurement.

Caffeine is the only compound in this jar whose behaviour can be described without hedging, because the amount is printed and the pharmacology is settled. It competes with adenosine at receptors in the brain, which is why it pushes back tiredness rather than adding energy.

At 5 mg the honest description is a trace. The survey of caffeine in ordinary drinks puts a five-ounce cup of ground roasted coffee at 85 mg and a cup of tea near 40. One gummy is under a seventh of the tea. The review that established the familiar daily ceiling sets 400 mg a day as the figure not associated with adverse effects in healthy adults.

Two groups should still register it rather than dismiss it. Anyone who has removed caffeine deliberately, for sleep or for palpitations, is entitled to know a supplement contains any at all. And anyone taking the gummy late in the evening is adding a stimulant at the wrong end of the day for no benefit, which is the practical argument for the morning slot.

The nitric-oxide story is the one every product in this category tells, and it is real chemistry. Arginine is the substrate nitric oxide synthase works on; nitric oxide relaxes smooth muscle in vessel walls; relaxed vessels carry more blood. Every step of that is textbook.

The gap is arithmetic rather than biological. The double-blind trial that put arginine on these labels gave 5 g a day for six weeks. The 2019 meta-analysis pooled the literature and located the effect between 1,500 mg and 5,000 mg a day. The pharmacokinetic work explains why the threshold is so high: oral arginine is extensively cleared before it reaches circulation, so a small dose disappears.

There is a second reason the amount matters here. Ordinary protein supplies roughly four to six grams of arginine a day. Anything a gummy adds on top of that sits well inside the day-to-day variation of an ordinary diet, which is the plainest way to say what a fraction of 82 mg can be expected to do.

No, and the paper usually offered as proof is the reason to say so clearly. Dell'Agli and colleagues measured icariin's inhibition of human phosphodiesterase-5 and reported an IC50 of 5.9 microM. In the same work they built synthetic derivatives; the best of them came in at 75 nM, against sildenafil's 74 nM in their assay.

Two things follow. The natural compound is roughly eighty times weaker than a laboratory molecule which itself only draws level with the drug. And the comparison was made in a dish, with a purified compound, at a concentration nobody has shown an oral dose can reach in a person.

What exists in humans is a pharmacokinetic study of standardised epimedium extract, which measured what appears in blood rather than what happens afterwards, and one placebo-controlled crossover in an unrelated condition. There is no human trial of icariin for this use, at any dose.

The useful way to hold both columns at once is to treat the jar as a routine with a trace stimulant in it rather than as a dose of anything. That framing costs the product its biggest marketing claims and keeps everything it can actually deliver, which is the trade this desk would rather make.

It is also why the results timeline on this website starts at three to four weeks rather than at day one, and why the 60-day window is the number to plan the trial around.